AFEYAN NOUBAR 4

What Happened Noubar Afeyan, a director of Moderna, was granted a derivative award on May 6, 2026 covering 12,908 shares. The reported acquisition price is $0.00 (i.e., no cash paid at grant). The filing classifies the transaction as an award/grant (derivative), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-06; Form 4 filed: 2026-05-08 (timely).
• Security: derivative award covering 12,908 shares; reported price $0.00; reported cash value $0 (grant may have future value).
• Shares owned after transaction: not specified in the provided report excerpt.
• Footnote: The option will become fully vested and exercisable on the earlier of May 6, 2027 or Moderna's next Annual Meeting of Shareholders, subject to continued service.
• Filing status: timely (no late-filing flag in the provided data).

Context This was a compensation grant of a derivative instrument (an option per the footnote), not a market purchase or sale. Such awards are commonly used to align executives/directors with shareholder interest; they only realize value if the underlying stock appreciates and vesting/exercise conditions are met. The grant itself does not indicate immediate buying or selling by the insider.